Relmada Therapeutics (NASDAQ:RLMD) Trading Down 3.3%

Relmada Therapeutics, Inc. (NASDAQ:RLMD) fell 3.3% during trading on Monday . The company traded as low as $3.70 and last traded at $3.87. 178,113 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 254,496 shares. The stock had previously closed at $4.00.

Relmada Therapeutics Trading Down 1.3 %

The business’s fifty day moving average is $5.17 and its 200 day moving average is $3.98. The firm has a market capitalization of $116.46 million, a P/E ratio of -1.18 and a beta of 0.19.

Relmada Therapeutics (NASDAQ:RLMD) last released its earnings results on Tuesday, March 19th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.04. As a group, sell-side analysts predict that Relmada Therapeutics, Inc. will post -3.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Relmada Therapeutics news, insider Chuck Ence bought 14,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The shares were acquired at an average cost of $3.87 per share, for a total transaction of $56,115.00. Following the acquisition, the insider now directly owns 25,300 shares of the company’s stock, valued at $97,911. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Chuck Ence bought 14,500 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were acquired at an average cost of $3.87 per share, with a total value of $56,115.00. Following the completion of the transaction, the insider now directly owns 25,300 shares in the company, valued at approximately $97,911. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Maged Shenouda bought 6,875 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was purchased at an average cost of $4.06 per share, for a total transaction of $27,912.50. Following the completion of the transaction, the chief financial officer now owns 34,903 shares of the company’s stock, valued at $141,706.18. The disclosure for this purchase can be found here. Insiders have acquired 91,176 shares of company stock worth $350,305 in the last ninety days. 13.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. purchased a new position in Relmada Therapeutics during the third quarter valued at approximately $48,000. TD Asset Management Inc grew its position in Relmada Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock valued at $75,000 after purchasing an additional 12,500 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Relmada Therapeutics during the fourth quarter valued at approximately $243,000. Silverarc Capital Management LLC purchased a new position in Relmada Therapeutics during the third quarter valued at approximately $300,000. Finally, Vestal Point Capital LP purchased a new position in Relmada Therapeutics during the fourth quarter valued at approximately $476,000. 45.24% of the stock is owned by hedge funds and other institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.